Your browser doesn't support javascript.
Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality.
Feher, Michael; Joy, Mark; Munro, Neil; Hinton, William; Williams, John; de Lusignan, Simon.
  • Feher M; Clinical Informatics and Health Outcomes Research Group. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. Electronic address: michael.feher@phc.ox.ac.uk.
  • Joy M; Clinical Informatics and Health Outcomes Research Group. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Munro N; Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.
  • Hinton W; Clinical Informatics and Health Outcomes Research Group. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Williams J; Clinical Informatics and Health Outcomes Research Group. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • de Lusignan S; Clinical Informatics and Health Outcomes Research Group. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Atherosclerosis ; 339: 55-56, 2021 12.
Article in English | MEDLINE | ID: covidwho-1509574
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fenofibrate / Pharmaceutical Preparations / COVID-19 Limits: Humans Language: English Journal: Atherosclerosis Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Fenofibrate / Pharmaceutical Preparations / COVID-19 Limits: Humans Language: English Journal: Atherosclerosis Year: 2021 Document Type: Article